- Founded in 2004 in Surat as Ami Organics, making advanced intermediates for cardiac and CNS drugs.
- Its September 2021 IPO was subscribed 64x and listed at a premium.
- It began making lithium-ion electrolyte additives in 2023, one of only two listed Indian players in the category.
- Renamed Acutaas Chemicals in 2024 to reflect a portfolio spanning agrochemicals, pigments, photographic chemicals and battery materials.
- 2004 Naresh Vijaykumar Patel founds Ami Organics in Surat, focused on advanced intermediates for cardiac and central-nervous-system drugs.
- 2007 The business is reorganised under Anand Desai and manufacturing capacity expands at Sachin GIDC.
- 2014 It builds a portfolio of advanced intermediates for high-volume APIs across cardiovascular, anti-diabetic and CNS drugs, with long-term contracts with Indian and global formulators.
- Sep 2021 Ami Organics lists at ₹610, subscribed 64x, and opens at a premium.
- Apr 2022 It acquires Baba Fine Chem’s active-pharmaceutical-ingredient business, adding Maharashtra geography and fresh API capability.
- 2023 It begins commercial production of electrolyte additives for lithium-ion battery cells, becoming one of two listed Indian companies in the category.
- 2024 The company is renamed Acutaas Chemicals, reflecting expansion into agrochemicals, dyes, pigments, photographic chemicals and battery materials.
- FY25 Revenue runs around ₹800 crore as the battery-materials revenue line begins to materialise.
- 2025 Indian lithium-ion cell manufacturing scales, Reliance, Ola Electric, Exide and Amara Raja all need electrolyte additives, and Acutaas scales with them.
- 2026 Management flags battery materials as a primary medium-term growth driver, with new capacity at Sachin and Jhagadia coming online.
Acutaas Chemicals, the company that listed as Ami Organics, spent more than fifteen years building a quiet specialty-chemicals franchise before adding the leg that could define its next decade: battery materials. The 2024 rename was the signal that the story is shifting from pharmaceutical intermediates to the applications of the electric economy. Here is the journey, year by year.
The pattern is the point
Acutaas built a quiet specialty-chemicals franchise for over fifteen years before adding battery materials as its next leg, and the rename was a signal that the coming decade is about applications, not just APIs. The companies that turn into investable themes are usually the ones that built the platform before the market was watching, which is exactly what happened here.
